<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902953</url>
  </required_header>
  <id_info>
    <org_study_id>2013-02-05</org_study_id>
    <nct_id>NCT01902953</nct_id>
  </id_info>
  <brief_title>Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)</brief_title>
  <official_title>Prospective, Open-Label, Ex Vivo Comparison Study of Lymphoseek® and Vital Blue Dye (VBD) as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC) Patients' Excised Colon w/ Abdominal Lymphatic Bed</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      45 patients undergoing a colon (large bowel/intestine)removal operation for the diagnosis of&#xD;
      colon cancer will be included in this study. During colon operation the affected portion of&#xD;
      the colon is removed. In addition, lymph nodes are included in the specimen and evaluated by&#xD;
      a pathologist. Analysis of the lymph nodes in the specimen are important because this is an&#xD;
      important aspect of determining the stage of the cancer.&#xD;
&#xD;
      Once the standard technique is used for the colon removal operation and the specimen is&#xD;
      removed it will be injected with two drugs to help identify the lymph nodes. One is a blue&#xD;
      dye and the other a radiotracer. The colon and ALL of the lymph nodes will then be sent for&#xD;
      the standard pathologic evaluation. The patient themselves will never be injected with these&#xD;
      drugs being used for research.&#xD;
&#xD;
      Following the standard lymph node evaluation, an additional pathologist at an outside&#xD;
      research facility will further examine the lymph nodes in the specimen using more in depth&#xD;
      techniques which are above and beyond the standard of care.&#xD;
&#xD;
      The results of all the pathologic tests will be conveyed to the surgeon of record to help in&#xD;
      their decision making regarding further treatment.&#xD;
&#xD;
      The study hypothesis is that radiotracer will be at least as effective as blue dye in&#xD;
      identifying the lymph nodes most likely to harbor cancer cells (sentinel nodes). Once&#xD;
      identified, these sentinel nodes can then undergo a more in depth review leading to improved&#xD;
      staging of colorectal cancer and more accurate treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single center, open-label, within patient's tissue ex vivo comparative study&#xD;
      of Lymphoseek (Lymphoseek (Technetium Tc 99m Tilmanocept) is a radiotracer that accumulates&#xD;
      in lymphatic tissue by binding to a mannose binding receptor that resides on the surface of&#xD;
      dendritic cells and macrophages. Lymphoseek has a diameter of about 5 nm, which is&#xD;
      substantially smaller than current radiolabeled agents used for targeting lymphoid tissue.&#xD;
      Lymphoseek's small diameter permits enhanced diffusion into lymph nodes and blood&#xD;
      capillaries, resulting in a rapid injection site clearance. Upon entry into the blood, the&#xD;
      agent binds to receptors in the liver or is filtered by the kidney and accumulates in the&#xD;
      bladder.)and vital blue dye (Patent Bleu V) in the detection of excised lymph nodes in&#xD;
      patients with known cancer of the colon.&#xD;
&#xD;
      The colon segment with tumor and the anticipated involved nodal bed will be removed intact.&#xD;
      After the surgical procedure is completed, the specimen is instantly taken to an extra table&#xD;
      in the operating room. It is performed just after the specimen is taken out. The colonic&#xD;
      specimen is incised longitudinally on the antimesenteric side.&#xD;
&#xD;
      Lymphatic mapping is employed on the specimen by using first injection Lymphoseek (50 µg/2&#xD;
      mCi) in 0.1-1.0 ml, followed in 15-30 min by 1 ml 1% blue dye, each injected subserosally and&#xD;
      submucosally around the tumor (peritumoral sites employed) by using tuberculin syringe. After&#xD;
      5-7 minutes of massage with little circulatory movements on the lesion, the marking agents&#xD;
      are moved into the lymphatic paths to the sentinel lymph nodes(SLN)in the mesentery.&#xD;
&#xD;
      By low level diathermy, sharp dissection of lymphatic path(s) to the SLN(s) may be existent.&#xD;
&#xD;
      Blue nodes shall be removed first by visual inspection. This inspection and dissection shall&#xD;
      last not longer than 20 minutes. Each blue node will then be assessed for counts as well as&#xD;
      color and the &quot;hot&quot; rule (3σ) applied as described below.&#xD;
&#xD;
      Following blue node removal, each sentinel lymph node can be removed from the basin and&#xD;
      marked before the specimen is submitted for pathologic appraisal.&#xD;
&#xD;
      The Lymphoseek-designated (localized) lymph nodes are defined as lymph nodes that have a&#xD;
      gamma detector count greater than the sum of 3 square roots of the mean background count&#xD;
      (i.e., standard deviation) added to the mean background count. This is referred to hereafter&#xD;
      as the &quot;3σ rule&quot; and as the &quot;threshold criteria&quot;. If the gamma detector used cannot obtain&#xD;
      gamma counts in three 2-second intervals, then one 10-second count may be used to detect&#xD;
      gamma counts. Any lymph node count not meeting this threshold criterion will be considered a&#xD;
      negative (non-localized) finding. The background count may be obtained by taking the 2-second&#xD;
      counts or the 10 second counts with the handheld gamma probe extended at least 100 cm away&#xD;
      from the injection site and the probe pointed away from anyLymphoseek source (syringes,&#xD;
      injection site, isotope-contaminated materials).&#xD;
&#xD;
      Probing of the area will be complete when all selected node counts are negative by use of the&#xD;
      threshold criteria. The surgeon will continue with visualization and palpation according to&#xD;
      local practice to ensure that no grossly positive lymph nodes remain at the site of&#xD;
      resection. To confirm the in vivo procedure, assessment of presence of a blue hue and a set&#xD;
      of three 2-second counts or one 10-second count will be recorded for the excised lymph nodes.&#xD;
      The mean count of the ex vivo lymph nodes will be compared to the mean of room background&#xD;
      counts, and the same threshold criteria used to determine a positive finding for the in vivo&#xD;
      nodes will be applied to the ex vivo specimens.&#xD;
&#xD;
      All removed lymph nodes will be sent to pathology for further evaluation. All lymph nodes&#xD;
      will undergo enhanced pathological evaluation including serial sectioning with H&amp;E staining&#xD;
      as well as immunohistochemical (IHC) markers A- The primary objective of efficacy is the&#xD;
      concordance of in vivo detection rates of Lymphoseek and VBD in excised lymph nodes as tissue&#xD;
      phenotype is confirmed by histology.&#xD;
&#xD;
      B- The primary objective is the assessment of the excised lymph node(s) to confirm the&#xD;
      presence/absence of tumor metastases in all nodes and a contrast of pathology findings in per&#xD;
      agent-found nodes versus all non-agent-based removed nodes.&#xD;
&#xD;
      Secondary evaluations will include localization rates (identification of any hot and/or blue&#xD;
      node), degree of localization (node number/patient's ex vivo total tissue), counts localized&#xD;
      per node, and time to localization and stabilization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Lymphoseek for Detection of Sentinel Nodes</measure>
    <time_frame>0-7 days</time_frame>
    <description>Number of Participants in Concordance of in vivo detection rates of Lymphoseek and VBD in excised lymph nodes as tissue phenotype is confirmed by histology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Localization Rates</measure>
    <time_frame>On the day of surgery i.e. day 0 of index operation</time_frame>
    <description>Number of Participants with secondary evaluations will include localization rates (identification of any hot and/or blue node),</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Lymphoseek and VBD SLN dissection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ex-Vivo Lymphoseek and VBD SLN dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lymphoseek and VBD Sln dissection</intervention_name>
    <description>See detailed description of study design</description>
    <arm_group_label>Lymphoseek and VBD SLN dissection</arm_group_label>
    <other_name>SLN dissection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has provided written informed consent with Health Insurance Portability&#xD;
             and Accountability Act (HIPAA) authorization.&#xD;
&#xD;
          -  The patient has a diagnosis of colon cancer and is a candidate for surgical&#xD;
             intervention, with ex vivo lymph node mapping being a part of the surgical plan.&#xD;
&#xD;
          -  The patient is at least 18 years of age at the time of consent.&#xD;
&#xD;
          -  The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             Grade 0 - 2.&#xD;
&#xD;
          -  The patient has a clinical negative node status at the time of study entry (i.e.,&#xD;
             Tis-4, N0, M0).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has clinical or radiological evidence of metastatic cancer including&#xD;
             palpably abnormal or enlarged lymph nodes.&#xD;
&#xD;
          -  The patient has undergone node basin surgery of any type or radiation to the nodal&#xD;
             basin(s).&#xD;
&#xD;
          -  The patient has undergone radiation therapy or chemotherapy treatment within the&#xD;
             previous 45 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danny A Sherwinter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>July 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <results_first_submitted>November 14, 2018</results_first_submitted>
  <results_first_submitted_qc>May 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2020</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Danny A Sherwinter</investigator_full_name>
    <investigator_title>Attending, Surgery</investigator_title>
  </responsible_party>
  <keyword>Sentinel lymph nodes</keyword>
  <keyword>colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>immunohistochemistry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT01902953/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lymphoseek and VBD SLN Dissection</title>
          <description>Ex-Vivo Lymphoseek and VBD SLN dissection&#xD;
Lymphoseek and VBD Sln dissection: See detailed description of study design</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lymphoseek and VBD SLN Dissection</title>
          <description>Ex-Vivo Lymphoseek and VBD SLN dissection&#xD;
Lymphoseek and VBD Sln dissection: See detailed description of study design</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.94" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Lymphoseek for Detection of Sentinel Nodes</title>
        <description>Number of Participants in Concordance of in vivo detection rates of Lymphoseek and VBD in excised lymph nodes as tissue phenotype is confirmed by histology.</description>
        <time_frame>0-7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lymphoseek and VBD SLN Dissection</title>
            <description>Ex-Vivo Lymphoseek and VBD SLN dissection&#xD;
Lymphoseek and VBD Sln dissection: See detailed description of study design</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Lymphoseek for Detection of Sentinel Nodes</title>
          <description>Number of Participants in Concordance of in vivo detection rates of Lymphoseek and VBD in excised lymph nodes as tissue phenotype is confirmed by histology.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Localization Rates</title>
        <description>Number of Participants with secondary evaluations will include localization rates (identification of any hot and/or blue node),</description>
        <time_frame>On the day of surgery i.e. day 0 of index operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lymphoseek and VBD SLN Dissection</title>
            <description>Ex-Vivo Lymphoseek and VBD SLN dissection&#xD;
Lymphoseek and VBD Sln dissection: See detailed description of study design</description>
          </group>
        </group_list>
        <measure>
          <title>Localization Rates</title>
          <description>Number of Participants with secondary evaluations will include localization rates (identification of any hot and/or blue node),</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lymphoseek and VBD SLN Dissection</title>
          <description>Ex-Vivo Lymphoseek and VBD SLN dissection&#xD;
Lymphoseek and VBD Sln dissection: See detailed description of study design</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Danny Sherwinter</name_or_title>
      <organization>Maimonides</organization>
      <phone>7182837952</phone>
      <email>dsherwinter@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

